- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00986024
Resistance and/or Endurance Training, What is Most Effective in Prevention of Cardiovascular Diseases?
Strength Training Versus Aerobic Interval Training to Modify Risk Factors of the Metabolic Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the Western world, approximately 25% of young to middle-aged adults have metabolic syndrome. There seem to be a strong age-dependence in the prevalence of the metabolic syndrome, but the incidence rises rapidly within adolescents and middle-aged groups and follows the development of obesity in the general population. Metabolic syndrome confers an increased risk of coronary heart disease, cardiovascular disease, and premature death; therefore, effective and affordable strategies to combat the syndrome would be of great individual and social importance.
Despite the general agreement that moderate-intensity physical activity for a minimum of 30 min five days per week or vigorous-intensity aerobic physical activity for a minimum of 20 min three days a week promote and maintain health, the optimal training regime to treat metabolic syndrome and its associated cardiovascular abnormalities remains uncertain.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Having metabolic syndrome according to international diabetes foundations definition (IDF).
Exclusion Criteria:
- Unstable angina pectoris
- Uncompensated heart failure
- Myocardial infarction during the past 4 weeks
- Complex ventricular arrhythmias
- Kidney failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: control group
|
|
|
Experimental: aerobic exercise
|
carried out 3 times per week for 12 weeks
|
|
Experimental: strength training
|
carried out 3 times per week for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
proinflammatory markers
Time Frame: 12 weeks
|
circulating interleukin-18 and interleukin-6
|
12 weeks
|
Collaborators and Investigators
Investigators
- Study Director: Ulrik Wisløff, md prof, Norwegian University of Science and Technology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 460150
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.